Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2024 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025
August 29, 2024 07:30 ET
|
Big4Bio
New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week
Appointment of Chase Hall, M.D., as Chief Medical Advisor
August 28, 2024 09:01 ET
|
Polarean
DURHAM, NC and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs,...
Vor Bio to Participate in Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
redalpine closes largest fund to date, $200M RAC VII, and announces new London office
August 27, 2024 08:00 ET
|
Redalpine
Zurich, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Leading European venture capital firm redalpine today announced the final close of its largest-ever fund, redalpine capital VII (RAC VII), at $200M....
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
August 26, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global...
Halberd Corp. Issues Letter to Shareholders
August 26, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp. - Taking a Moment to Recenter Our Technical Progress
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 26, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...